P. McKenna

发表

Comment on Jameson et al.: Prevalence of Antibodies against Hantaviruses in Serum and Saliva of Adults Living or Working on Farms in Yorkshire, United Kingdom

M. Van Ranst, J. Clement, P. McKenna, 2014, Viruses.

A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance

D. Stammers, B. Larder, S. Kemp, 2002, Journal of Virology.

Human Immunodeficiency Virus Infection Transcriptase Inhibitor for Treatment of Deoxycytidine Nucleoside Reverse Toxicity Profile of SPD 754 , a New In Vitro Antiretroviral Activity and In Vitro

D. Taylor, B. Allard, P. McKenna, 2005 .

Hantavirus pulmonary syndrome in New England and Europe.

P. McKenna, P. Colson, J. Clement, 1994, The New England journal of medicine.

Hantavirus epidemic In Europe, 1993

P. Sureau, B. Hoen, P. Rollin, 1994, The Lancet.

Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick‐borne encephalitis

K. Stiasny, F. Heinz, M. Kundi, 1996, Journal of medical virology.

[Epidemic of hantavirus disease in Entre-Sambre-et-Meuse: year 1992-1993. Clinical and biological aspects].

J. Clement, P. McKenna, P. Colson, 1995, Acta clinica Belgica.

Epidemiology and laboratory diagnosis of hantavirus (HTV) infections.

A. Osterhaus, J. Groen, J. Clement, 1995, Acta clinica Belgica.

Serological evidence of hantavirus disease in Northern Ireland

J. Clement, C. Mccaughey, P. McKenna, 1994, Journal of medical virology.

Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates

B. Larder, M. D. Miller, P. Harrigan, 2002, Antimicrobial Agents and Chemotherapy.

In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection

D. Taylor, R. Bethell, N. Nguyen-ba, 2006, Antimicrobial Agents and Chemotherapy.

The hantaviruses of Europe: from the bedside to the bench.

T. Avšič-Županc, J. Clement, P. McKenna, 1997, Emerging infectious diseases.

Investigation of Baseline Susceptibility to Protease Inhibitors in HIV-1 Subtypes C, F, G and Crf02_Ag

Anne-Mieke Vandamme, Koen Deforche, Ricardo Jorge Camacho, 2005, Antiviral therapy.

Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G

Anne-Mieke Vandamme, Koen Deforche, Joke Snoeck, 2005, AIDS.

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.

K. Hertogs, B. Larder, M. Wallace, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy.

L. Bacheler, P. Harrigan, Z. Brumme, 2007, AIDS research and human retroviruses.

Parrallelism Between Lyme and Tick-Borne Encephalitis (TBE) Sero-Epidemiology Following Occupational Exposure in S. Germany

H. Leirs, A. Osterhaus, C. Kunz, 1994 .

Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.

D. Podzamczer, J. Gatell, M. Arnedo, 2003, The Journal of infectious diseases.

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors

L. Bacheler, B. Wynhoven, P. Harrigan, 2005, AIDS.

DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping

F. Chiafari, E. Pomarol-Clotet, Johnson, 2009, CNS Spectrums.